Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE® (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. Both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUS® (insulin glargine), allowing for substitution at the pharmacy counter. SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris and Biocon Biologics, are now available in the U.S. market.

The currently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the end of the 2021 calendar year. To further expand access to insulins, Viatris has established a range of options to help patients, including: Patient Assistance Program, which may provide free medicine to eligible patients with demonstrated financial need. Copay Program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $0 per 30-day supply.

Voucher for new patients to receive five (5) free 3 mL pens or two (2) free 10 mL vials. Cash-Pay Programs to reduce out-of-pocket costs when paying at the pharmacy counter. Medicare Part D Senior Savings Model Insulin Medicare Savings Program, with membership beginning in 2022, which limits patient out-of-pocket costs during all phases of coverage (deductible, initial coverage and coverage gap) to no more than $35 for a month's supply.